NCT01590810 - A Single Rising Dose Study of MK-8150 (MK-8150-001) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2012

Primary Completion Date

January 24, 2013

Study Completion Date

February 5, 2013

Conditions

HypertensionIsolated Systolic Hypertension (ISH)

Interventions

DRUG

MK-8150 2.0 mg

Single oral 2.0-mg dose of MK-8150

DRUG

MK-8150 10 mg

Single oral 10-mg dose of MK-8150

DRUG

MK-8150 40 mg

Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)

DRUG

MK-8150 90 mg

Single oral 90-mg dose of MK-8150

DRUG

MK-8150 5.0 mg

Single oral 5.0-mg dose of MK-8150

DRUG

MK-8150 20 mg

Single oral 20-mg dose of MK-8150

DRUG

MK-8150 60 mg

Single oral 60-mg dose of MK-8150

DRUG

MK-8150 120 mg

Single oral 120-mg dose of MK-8150

DRUG

MK-8150 160 mg

Single oral 160-mg dose of MK-8150

DRUG

MK-8150 320 mg

Single oral 320-mg dose of MK-8150

DRUG

MK-8150 600 mg

Single oral 600-mg dose of MK-8150

DRUG

MK-8150 900 mg

Single oral 900-mg dose of MK-8150

DRUG

MK-8150 1200 mg

Single oral 1200-mg dose of MK-8150

DRUG

Placebo for MK-8150

Single oral dose-matched dose of Placebo for MK-8150

DRUG

MK-8150 50 mg

Single oral 50-mg dose of MK-8150

DRUG

MK-8150 100 mg

Single oral 100-mg dose of MK-8150

DRUG

MK-8150 200 mg

Single oral 200-mg dose of MK-8150

DRUG

MK-8150 400 mg

Single oral 400-mg dose of MK-8150

DRUG

MK-8150 500 mg

Single oral 500-mg dose of MK-8150

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY